Portal de Periódicos da CAPES

DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER

2000; Lippincott Williams & Wilkins; Volume: 163; Issue: 3 Linguagem: Inglês

10.1016/s0022-5347(05)67815-9

1527-3792

Aaron Weitzman, Gary Shelton, Nancy Zuech, Cindy E. Owen, Timothy Judge, Mitchell C. Benson, Ihor S. Sawczuk, Aaron E. Katz, Carl A. Olsson, Emilia Bagiella, Charles Pfaff, Jeffrey H. Newhouse, Daniel P. Petrylak,

Hormonal and reproductive studies

No AccessJournal of UrologyCLINICAL UROLOGY: Original Articles1 Mar 2000DEXAMETHASONE DOES NOT SIGNIFICANTLY CONTRIBUTE TO THE RESPONSE RATE OF DOCETAXEL AND ESTRAMUSTINE IN ANDROGEN INDEPENDENT PROSTATE CANCER AARON L. WEITZMAN, GARY SHELTON, NANCY ZUECH, CINDY ENGLAND OWEN, TIMOTHY JUDGE, MITCHELL BENSON, IHOR SAWCZUK, AARON KATZ, CARL A. OLSSON, EMILIA BAGIELLA, CHARLES PFAFF, JEFFREY H. NEWHOUSE, and DANIEL P. PETRYLAK AARON L. WEITZMANAARON L. WEITZMAN , GARY SHELTONGARY SHELTON , NANCY ZUECHNANCY ZUECH , CINDY ENGLAND OWENCINDY ENGLAND OWEN , TIMOTHY JUDGETIMOTHY JUDGE , MITCHELL BENSONMITCHELL BENSON , IHOR SAWCZUKIHOR SAWCZUK , AARON KATZAARON KATZ , CARL A. OLSSONCARL A. OLSSON , EMILIA BAGIELLAEMILIA BAGIELLA , CHARLES PFAFFCHARLES PFAFF , JEFFREY H. NEWHOUSEJEFFREY H. NEWHOUSE , and DANIEL P. PETRYLAKDANIEL P. PETRYLAK View All Author Informationhttps://doi.org/10.1016/S0022-5347(05)67815-9AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: We evaluated the independent response rate of dexamethasone before docetaxel and estramustine administration as measured by changes in serum prostate specific antigen (PSA) in patients with androgen independent prostate cancer. Materials and Methods: A total of 12 patients received 20 mg. dexamethasone orally every 6 hours for 3 doses repeated every 3 weeks before starting cytotoxic therapy with estramustine and docetaxel. After progression on dexamethasone 280 mg. estramustine orally 3 times daily on days 1 to 5 and 70 mg./m.2 docetaxel intravenously for 1 hour on day 2 were given. Results: None of the patients initially treated with dexamethasone monotherapy (median 1 cycle, range 1 to 5) had a PSA decline of 50% or greater. Median PSA increase on monotherapy was 47% (range 0% to 22%). On estramustine and docetaxel therapy PSA decreased 50% or greater in 11 patients (92%, 95% confidence intervals [CI] 60 to 99) and 80% or greater in 7 (58%, 95% CI 29 to 84), and normalized in 5 (42%, 95% CI 16 to 71), with a median duration of response of 153 (range 42 to 371), 132 (range 84 to 287) and 84 (range 21 to 174) days, respectively. Median times to reach 50% and 80% decreases in baseline PSA were 21 (range 21 to 209) and 63 (range 21 to 138) days, respectively. In 9 patients (75%, 95% CI 43 to 93) PSA decreased at least 50% by week 9. Of 4 patients with bidimensionally measurable disease 3 had a partial response. Median time to progression was 263 days (range 91 to 378). Conclusions: Administration of 20. mg. dexamethasone orally every 6 hours for 3 doses every 3 weeks does not significantly contribute to the PSA response rate of estramustine and docetaxel. References 1 : Unique synergism or antagonism of combinations of chemotherapeutic and hormonal agents in human prostate cancer cell lines. Br J Uro1997; l79: 196. Google Scholar 2 : Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines. Cancer Res1992; 52: 4433. Google Scholar 3 : Phase I/II studies of the combination of estramustine and docetaxel in hormone-refractory prostate cancer. Semin Oncol1999; 17: 26. Google Scholar 4 : Estramustine depolymerizes microtubules by binding to tubulin. Cancer Res1993; 53: 4573. Google Scholar 5 : Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol1988; 107: 2647. Google Scholar 6 : P-glycoprotein binding and modulation of the multidrug-resistant phenotype by estramustine. J Natl Cancer Inst1994; 86: 688. Google Scholar 7 : Modulation of the function of P-glycoprotein by estramustine. J Natl Cancer Inst1994; 86: 723. Google Scholar 8 : Inhibition of prostate cancer growth by estramustine and etoposide: evidence for interaction at the nuclear matrix. J Urol1993; 149: 1622. Link, Google Scholar 9 : Docetaxel. J Clin Oncol1995; 13: 2643. Google Scholar 10 : Studies with RP 56975 (taxotere): a semisynthetic analogue of taxol. J Natl Canc Inst1991; 83: 288. Google Scholar 11 : Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J Clin Oncol1999; 17: 958. Google Scholar 12 : Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann Oncol1999; 1: 33. Google Scholar 13 : A phase II study of docetaxel, estramustine, and low dose hydrocortisone in hormone refractory prostate cancer. Proc Am Soc Clin Oncol1999; 18: 321A. Google Scholar 14 : A phase II study evaluating a one day course of estramustine phosphate (EMP) and docetaxel (D) in patients with hormone refractory prostate cancer (HRPC). Proc Am Soc Clin Oncol1999; 18: 322A. Google Scholar 15 : Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer. J Clin Oncol1997; 15: 3149. Google Scholar 16 : Treatment of metastatic prostatic cancer with low-dose prednisone: evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol1989; 7: 590. Google Scholar 17 : Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol1996; 14: 1756. Google Scholar 18 : Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology1998; 52: 252. Google Scholar 19 : Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the cancer and leukemia group B 9182 study. J Clin Oncol1999; 17: 2056. Google Scholar 20 : Antitumor activity of suramin in hormone-refractory prostate cancer controlling for hydrocortisone treatment and flutamide withdrawal as potentially confounding variables. Cancer1995; 76: 453. Google Scholar 21 : Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol1995; 13: 2208. Google Scholar 22 : Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer1995; 76: 96. Google Scholar 23 : Eligibility and response guidelines for phase II clinical trial in androgen independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol1999; 17: 3461. Google Scholar 24 : Optimal two-stage designs for phase II clinical trials. Control Clin Trials1989; 10: 1. Google Scholar 25 : Taxol in advanced hormone-refractory carcinoma of the phase II trial of the Eastern Cooperative Oncology Group. Cancer1993; 72: 2457. Google Scholar 26 : Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol1997; 15: 3156. Google Scholar 27 : A phase II randomized trial of megestrol acetate or dexamethasone in the treatment of hormonally refractory advanced carcinoma of the prostate. Cancer1990; 66: 655. Google Scholar 28 : Androgen and glucocorticoid receptors in the stroma and epithelium of prostatic hyperplasia and carcinoma. Clin Cancer Res1996; 2: 889. Google Scholar From the Departments of Medicine, Urology, Radiology and Biostatistics, Division of Medical Oncology, Columbia Presbyterian Medical Center, New York, New York© 2000 by American Urological Association, Inc.FiguresReferencesRelatedDetailsCited byURAKAMI S, IGAWA M, KIKUNO N, YOSHINO T, KISHI H, SHIGENO K and SHIINA H (2018) Combination Chemotherapy with Paclitaxel, Estramustine and Carboplatin for Hormone Refractory Prostate CancerJournal of Urology, VOL. 168, NO. 6, (2444-2450), Online publication date: 1-Dec-2002. Volume 163Issue 3March 2000Page: 834-837 Advertisement Copyright & Permissions© 2000 by American Urological Association, Inc.Keywordsestramustinedexamethasoneprostatic neoplasmsprostateMetricsAuthor Information AARON L. WEITZMAN More articles by this author GARY SHELTON More articles by this author NANCY ZUECH More articles by this author CINDY ENGLAND OWEN More articles by this author TIMOTHY JUDGE More articles by this author MITCHELL BENSON More articles by this author IHOR SAWCZUK More articles by this author AARON KATZ More articles by this author CARL A. OLSSON More articles by this author EMILIA BAGIELLA More articles by this author CHARLES PFAFF More articles by this author JEFFREY H. NEWHOUSE More articles by this author DANIEL P. PETRYLAK More articles by this author Expand All Advertisement PDF downloadLoading ...